The active ingredients in the solution work by disrupting the fat cells, which are then naturally eliminated from the body over time
Regeneron, which reported profits from Dupixent sales recorded by Sanofi, announced fourth-quarter revenues of $3.70 billion, surpassing expectations, and announced a new dividend and $3 billion share buyback program
Specifically, it simultaneously targets three receptor pathways: GLP-1, GIP, and glucagon receptors
It means retatrutide does not just reduce calorie intake through appetite suppression, it also increases calorie burning
Here's a quick comparison: While dosing schedules appear similar, retatrutide's triple-receptor mechanism (GLP-1 + GIP + glucagon) produces different effects than dual-agonists like tirzepatide or single-agonists like semaglutide